Novartis subsidiary Sandoz launched a generic challenger to AbbVie’s Combigan on Thursday. The debut came less than two weeks after the FDA approved the generic ophthalmic solution.
Its arrival marks an expansion of Novartis’ ophthalmology portfolio — and represents new competition for Combigan, which generated $373 million in net revenues for AbbVie in 2021, according to the company’s latest earnings report.
“Fixed combinations of medicines to treat ocular hypertension can offer patients enhanced convenience, improved adherence, reduced exposure to preservatives and cost savings,” said Sandoz president Keren Haruvi in a statement. “We developed this important generic eye treatment in-house to expand patient access to high-quality, more affordable eye care for millions of U.S. patients.”